Horizon Pharma Plc

Find Ratings Reports
HZNP : NASDAQ : Health Technology
$14.94 | %
Today's Range: 14.93 - 15.19
Avg. Daily Volume: 1777500.0
03/16/18 - 4:00 PM ET

Financial Analysis

HORIZON PHARMA PLC's gross profit margin for the third quarter of its fiscal year 2017 is essentially unchanged when compared to the same period a year ago. Sales and net income have dropped, although the growth in revenues underperformed the average competitor within the industry, the net income growth did not. HORIZON PHARMA PLC has average liquidity. Currently, the Quick Ratio is 1.45 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.

At the same time, stockholders' equity ("net worth") has significantly decreased by 26.59% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.

Income Statement Q3 FY17 Q3 FY16
Net Sales ($mil)271.65273.7
EBITDA ($mil)74.32112.08
EBIT ($mil)4.1860.14
Net Income ($mil)-63.97-5.87

Balance Sheet Q3 FY17 Q3 FY16
Cash & Equiv. ($mil)637.21557.31
Total Assets ($mil)4169.453349.67
Total Debt ($mil)1897.581147.22
Equity ($mil)999.821361.98

Profitability Q3 FY17 Q3 FY16
Gross Profit Margin89.0191.54
EBITDA Margin27.3540.95
Operating Margin1.5421.97
Sales Turnover0.260.29
Return on Assets-11.86-0.36
Return on Equity-49.47-0.9
Debt Q3 FY17 Q3 FY16
Current Ratio1.642.01
Interest Expense31.7119.07
Interest Coverage0.133.15

Share Data Q3 FY17 Q3 FY16
Shares outstanding (mil)163.86161.23
Div / share0.00.0
Book value / share6.18.45
Institutional Own % n/a n/a
Avg Daily Volume1800672.02423684.0


SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. To use another comparison, its price-to-book ratio of 2.47 indicates a discount versus the S&P 500 average of 3.28 and a significant discount versus the industry average of 7.60. The price-to-sales ratio is similar to the S&P 500 average, but it is significantly below the industry average, indicating a discount. After reviewing these and other key valuation criteria, HORIZON PHARMA PLC proves to trade at a discount to investment alternatives within the industry.

1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
HZNP NM Peers 105.10   HZNP 8.90 Peers 17.82

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

HZNP's P/E is negative making this valuation measure meaningless.


Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

HZNP is trading at a significant discount to its peers.

1 2 3 4 5
premium   discount
  Price to
1 2 3 4 5
premium   discount
HZNP 8.61 Peers 14.20   HZNP NA Peers 0.51

Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.

HZNP is trading at a significant discount to its peers.


Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
HZNP 2.47 Peers 7.60   HZNP -3712.50 Peers -278.29

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

HZNP is trading at a significant discount to its peers.


Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, HZNP is expected to significantly trail its peers on the basis of its earnings growth rate.

1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
HZNP 2.26 Peers 25.39   HZNP 11.43 Peers 23.77

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

HZNP is trading at a significant discount to its industry on this measurement.


Lower. A sales growth rate that trails the industry implies that a company is losing market share.

HZNP significantly trails its peers on the basis of sales growth



Latest Stock Upgrades/Downgrades